The molecular signature of ductal carcinoma in situ (DCIS) in the breast is
not well understood. Erb-b2 receptor tyrosine kinase 2 (ERBB2 [formerly
known as HER2/neu]) positivity in DCIS is predictive of coexistent early
invasive breast carcinoma. The aim of this study is to identify the
gene-expression signature profiles of estrogen receptor (ER)/progesterone
receptor (PR)-positive, ERBB2, and triple-negative subtypes of DCIS.
Methods
Based on ER, PR, and ERBB2 status, a total of 18 high nuclear grade DCIS
cases with no evidence of invasive breast carcinoma were selected along with
6 non-neoplastic controls. The 3 study groups were defined as
ER/PR-positive, ERBB2, and triple-negative subtypes.
Results
A total of 49 genes were differentially expressed in the ERBB2 subtype
compared with the ER/PR-positive and triple-negative groups. PROM1 was
overexpressed in the ERBB2 subtype compared with ER/PR-positive and
triple-negative subtypes. Other genes differentially expressed included
TAOK1, AREG, AGR3, PEG10, and MMP9.
Conclusions
Our study identified unique gene signatures in ERBB2-positive DCIS, which may
be associated with the development of invasive breast carcinoma. The results
may enhance our understanding of the progression of breast cancer and become
the basis for developing new predictive biomarkers and therapeutic targets
for DCIS.
References
1.
ClarkS.E.,
WarwickJ.,
CarpenterR.Molecular subtyping of DCIS: heterogeneity of breast cancer
reflected in pre-invasive disease.Br J Cancer.2011; 104(1):
120–127.
2.
SgroiD.C.Preinvasive breast cancer.Annu Rev Pathol.2010; 5:
193–221.
3.
ValenzuelaM.,
JulianT.B.Ductal carcinoma in situ: biology, diagnosis, and new
therapies.Clin Breast Cancer.2007; 7(9):
676–681.
4.
AllegraC.J.,
AberleD.R.,
GanschowP.National Institutes of Health state-of-the-science conference
statement: diagnosis and management of ductal carcinoma in situ September
22-24, 2009.J Natl Cancer Inst.2010; 102(3):
161–169.
5.
PerouC.M.,
SørlieT.,
EisenM.B.Molecular portraits of human breast tumours.Nature.2000; 406(6797):
747–752.
6.
PerouC.M.,
JeffreyS.S.,
van de RijnM.Distinctive gene expression patterns in human mammary epithelial
cells and breast cancers.Proc Natl Acad Sci USA.1999; 96:
9212–9217.
7.
van't
VeerL.J.,
HongyueD.,
van de
VijverM.J.Gene expression profiling predicts clinical outcome of breast
cancer.Nature.2002; 415(6871):
530–536.
8.
BaoT.,
DavidsonN.E.Gene expression profiling of breast cancer.Adv Surg.2008; 42:
249–260.
9.
O'ConnellP.,
PekkelV.,
FuquaS.A.Analysis of loss of heterozygosity in 399 premalignant breast
lesions at 15 genetic loci.J Natl Cancer Inst.1998; 90(9):
697–703.
10.
BoeckerW.,
BuergerH.,
SchmitzK.Ductal epithelial proliferations of the breast: a biological
continuum? Comparative genomic hybridization and high-molecular-weight
cytokeratin expression patterns.J Pathol.2001; 195(4):
415–421.
11.
JonesC.,
MerrettS.,
ThomasV.A.Comparative genomic hybridization analysis of bilateral
hyperplasia of usual type of the breast.J Pathol.2003; 199(2):
152–156.
12.
BombonatiA.,
SgroiD.C.The molecular pathology of breast cancer
progression.J Pathol.2011; 233(2):
307–317.
13.
BuergerH.,
OtterbachF.,
SimonR.Comparative genomic hybridization of ductal carcinoma in situ of
the breast-evidence of multiple genetic pathways.J Pathol.1999; 187(4):
396–402.
14.
WolffB.,
HaradaS.Molecular pathology and molecular markers of ductal carcinoma
in-situ.Curr Cancer Ther Rev.2012; 8(3):
97–204.
15.
MeijnenP.,
PeterseJ.L.,
AntoniniN.Immunohistochemical categorisation of ductal carcinoma in situ of
the breast.Br J Cancer.2008; 98(1):
137–142.
16.
TamimiR.M.,
BaerH.J.,
MarottiJ.Comparison of molecular phenotype of ductal carcinoma in situ and
invasive breast cancer.Breast Cancer Res.2008; 10(4):
R67.
17.
HolmesP.,
LloydJ.,
ChervonevaI.Prognostic markers and long-term outcomes in ductal carcinoma in
situ of the breast treated with excision alone.Cancer.2011; 117(16):
3650–3657.
18.
HaradaS.,
MickR.,
RosesR.E.The significance of HER-2/ neu receptor positivity and
immunophenotype in ductal carcinoma in situ with early invasive
disease.J Surg Oncol.2011; 104(5):
458–465.
19.
RosesR.E.,
PaulsonE.C.,
SharmaA.HER-2/neu overexpression as a predictor for the transition from
in situ to invasive breast cancer.Cancer Epidemiol Biomarkers Prev.2009; 18(5):
1386–1389.
20.
LiaoN.,
ZhangG.C.,
LiuY.H.HER2-positive status is an independent predictor for coexisting
invasion of ductal carcinoma in situ of the breast presenting extensive DCIS
component.Pathol Res Pract.2011; 207(1):
1–7.
21.
WolffA.C.,
HammondM.E.,
HicksD.G.Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline update.Arch Pathol Lab Med.2014; 138(2):
241–256.
CarraroD.M.,
EliasE.V.,
AndradeV.P.Ductal carcinoma in situ of the breast: morphological and
molecular features implicated in progression.Biosci Rep.2014; 34(1):
piie00090.
24.
CastroN.P.,
OsorioC.A.,
TorresC.Evidence that molecular changes in cells occur before
morphological alterations during the progression of breast ductal
carcinoma.Breast Cancer Res.2008; 10(5):
R87.
25.
MaX.J.,
SalungaR.,
TuggleJ.T.Gene expression profiles of human breast cancer
progression.Proc Natl Acad Sci USA.2003; 100(10):
5974–5979.
26.
AbbaM.C.,
SunH.,
HawkinsK.A.Breast cancer molecular signatures as determined by SAGE:
correlation with lymph node status.Mol Cancer Res.2007; 5(9):
881–890.
27.
SchuetzC.S.,
BoninM.,
ClareS.E.Progression-specific genes identified by expression profiling of
matched ductal carcinomas in situ and invasive breast tumors, combining
laser capture microdissection and oligonucleotide microarray
analysis.Cancer Res.2006; 66(10):
5278–5286.
28.
VargasA.C.,
McCart
ReedA.E.,
WadellN.Gene expression profiling of tumor epithelial and stromal
compartments during breast cancer progression.Breast Cancer Res.2012; 135(1):
153–165.
29.
WuZ.J.,
MeyerC.A.,
ChoudhuryS.Gene expression profiling of human breast tissue samples using
SAGE-Seq.Genome Res.2010; 20(12):
1730–1739.
30.
ZajchowskiD.A.,
BartholdiM.F.,
GongY.Identification of gene expression profiles that predict the
aggressive behavior of breast cancer cells.Cancer Res.2001; 61(13):
5168–5178.
31.
EffiA.B.,
AmanN.A.,
KouiB.S.Breast cancer molecular subtypes defined by ER/PR and HER2
status: Association with clinicopathologic parameters in Ivorian
patients.Asian Pac J Cancer Prev.2016; 17(4):
1973–1978.
32.
AllredD.C.Ductal carcinoma in situ: terminology, classification, and
natural history.J Natl Cancer Inst Monogr.2010; 2010(41):
134–138.
33.
KretschmerC.,
Sterner-KockA.,
SiedentopfF.Identification of early molecular markers for breast
cancer.Mol Cancer.2011; 10(1):
15.
34.
TaïebN.,
MarescaM.,
GuoX.J.The first extracellular domain of the tumour stem cell marker
CD133 contains an antigenic ganglioside-binding motif.Cancer Lett.2009; 278(2):
164–173.
35.
SheridanC.,
KishimotoH.,
FuchsR.K.CD44+/CD24– breast cancer cells exhibit enhanced invasive
properties: an early step necessary for metastasis.Breast Cancer Res.2006; 8(5):
R59.
36.
BinZ.,
GuangboZ.,
YanG.Overexpression of B7-H3 in CD133+ colorectal cancer cells is
associated with cancer progression and survival in human
patients.J Surg Res.2014; 188(2):
396–403.
37.
ChenS.,
SongX.,
ChenZ.CD133 expression and the prognosis of colorectal cancer: a
systematic review and meta-analysis.PLoS One.2013; 8(2):
e56380.
38.
SnippertH.J.,
van EsJ.H.,
van den
BornM.Prominin-1/ CD133 marks stem cells and early progenitors in mouse
small intestine.Gastroenterology.2009; 136(7):
2187–2194.
39.
OshimaY.,
SuzukiA.,
KawashimoK.Isolation of mouse pancreatic ductal progenitor cells expressing
CD133 and c-Met by flow cytometric cell sorting.Gastroenterology.2007; 132(2):
720–732.
40.
KordesC.,
SawitzaI.,
Müller-MarbachA.CD133+ hepatic stellate cells are progenitor
cells.Biochem Biophys Res Commun.2007; 352(2):
410–417.
41.
SahlbergS.H.,
SpiegelbergD.,
GlimeliusB.Evaluation of cancer stem cell markers CD133, CD44, CD24:
association with AKT isoforms and radiation resistance in colon cancer
cells.PLoS One.2014; 9(4):
e94621.
42.
TangK.H.,
MaS.,
LeeT.K.CD133(+) liver tumor-initiating cells promote tumor angiogenesis,
growth, and self-renewal through neurotensin/ interleukin-8/CXCL1
signaling.Hepatology.2012; 55(3):
807–820.
43.
Holmberg
OlaussonK.,
MaireC.L.,
HaidarS.Prominin-1 (CD133) defines both stem and non-stem cell
populations in CNS development and gliomas.PLoS One.2014; 9(9):
e106694.
44.
LiY.,
HeY.,
QiuZ.CRTC2 and PROM1 expression in non-small cell lung cancer:
analysis by Western blot and immunohistochemistry.Tumour Biol.2014; 35(12):
11719–11726.
45.
NomuraA.,
BanerjeeS.,
ChughR.CD133 initiates tumors, induces epithelial-mesenchymal transition
and increases metastasis in pancreatic cancer.Oncotarget.2015; 6(10):
8313–8322.
46.
LingJ.,
KangY.,
ZhaoR.KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62
feedforward loops is required for development of pancreatic ductal
adenocarcinoma.Cancer Cell.2012; 21(1):
105–120.
47.
JungK.,
WangP.,
GutpaN.Profiling gene promoter occupancy of Sox2 in two phenotypically
distinct breast cancer cell subsets using chromatin immunoprecipitation and
genome-wide promoter microarrays.Breast Cancer Res.2014; 16(6):
470.
48.
LatorreE.,
CarelliS.,
RaimondiI.The ribonucleic complex HuR-MALAT1 represses CD133 expression and
suppresses epithelial-mesenchymal transition in breast
cancer.Cancer Res.2016; 76(9):
2626–2636.
49.
HinmanM.N.,
LouH.Diverse molecular functions of Hu proteins.Cell Mol Life Sci.2008; 65(20):
3168–3181.
50.
DraviamV.M.,
StegmeierF.,
NalepaG.A functional genomic screen identifies a role for TAO1 kinase in
spindle-checkpoint signalling.Nat Cell Biol.2007; 9(5):
556–564.
51.
SchulteI.,
BattyE.M.,
PoleJ.C.Structural analysis of the genome of breast cancer cell line
ZR-75-30 identifies twelve expressed fusion genes.BMC Genomics.2012; 13: 719.
52.
FunatomiH.,
ItakuraJ.,
IshiwataT.Amphiregulin antisense oligonucleotide inhibits the growth of
T3M4 human pancreatic cancer cells and sensitizes the cells to EGF
receptor-targeted therapy.Int J Cancer.1997; 72(3):
512–517.
53.
MaL.,
de
RoquancourtA.,
BertheauP.Expression of amphiregulin and epidermal growth factor receptor
in human breast cancer: analysis of autocriny and stromal-epithelial
interactions.J Pathol.2001; 194(4):
413–419.
54.
WillmarthN.E.,
EthierS.P.Autocrine and juxtacrine effects of amphiregulin on the
proliferative, invasive, and migratory properties of normal and neoplastic
human mammary epithelial cells.J Biol Chem.2006; 281(49):
37728–37737.
55.
SternlichtM.D.,
SunnarborgS.W.,
Kouros-MehrH.Mammary ductal morphogenesis requires paracrine activation of
stromal EGFR via ADAM17-dependent shedding of epithelial
amphiregulin.Development.2005; 132(17):
3923–3933.
56.
LiS.,
PlowmanG.D.,
BuckleyS.D.Heparin inhibition of autonomous growth implicates amphiregulin
as an autocrine growth factor for normal human mammary epithelial
cells.J Cell Physiol.1992; 153(1):
103–111.
57.
CastilloJ.,
ErrobaE.,
PerugorríaM.J.Amphiregulin contributes to the transformed phenotype of human
hepatocellular carcinoma cells.Cancer Res.2006; 66(12):
6129–6138.
58.
JohnsonG.R.,
SaekiT.,
GordonA.W.Autocrine action of amphiregulin in a colon carcinoma cell line
and immunocytochemical localization of amphiregulin in human
colon.J Cell Biol.1992; 118(3):
741–751.
59.
LiC.M.,
MargolinA.A.,
SalasM.PEG10 is a c-MYC target gene in cancer cells.Cancer Res.2006; 66(2):
665–672.
60.
LuxH.,
FlammannH.,
HafnerM.Genetic and molecular analyses of PEG10 reveal new aspects of
genomic organization, transcription and translation.PLoS One.2010; 5(1):
e8686.
61.
OkabeH.,
SatohS.,
FurukawaY.Involvement of PEG10 in human hepatocellular carcinogenesis
through interaction with SIAH1.Cancer Res.2003; 63(12):
3043–3048.
62.
TsouA.P.,
ChuangY.C.,
SuJ.Y.Overexpression of a novel imprinted gene, PEG10, in human
hepatocellular carcinoma and in regenerating mouse livers.J Biomed Sci.2003; 10(6 pt 1):
625–635.
63.
OnoR.,
KobayashiS.,
WagatsumaH.A retrotransposon-derived gene, PEG10, is a novel imprinted gene
located on human chromosome 7q21.Genomics.2001; 73(2):
232–237.
64.
AdamP.J.,
BoydR.,
TysonK.L.Comprehensive proteomic analysis of breast cancer cell membranes
reveals unique proteins with potential roles in clinical
cancer.J Biol Chem.2003; 278:
6482–6489.
65.
ObaczJ.,
TakacovaM.,
BrychtovaV.The role of AGR2 and AGR3 in cancer: similar but not
identical.Eur J Cell Biol.2015; 94(3-4):
139–147.
66.
GrayT.A.,
MacLaineN.J.,
MichieC.O.Anterior Gradient-3: a novel biomarker for ovarian cancer that
mediates cisplatin resistance in xenograft models.J Immunol Methods.2012; 378(1-2):
20–32.
67.
FletcherG.C.,
PatelS.,
TysonK.hAG-2 and hAG-3, human homologues of genes involved in
differentiation, are associated with oestrogen receptor-positive breast
tumours and interact with metastasis gene C4.4a and
dystroglycan.Br J Cancer.2003; 88(4):
579–585.
68.
LacroixM.Significance, detection and markers of disseminated breast cancer
cells.Endocr Relat Cancer.2006; 13(4):
1033–1067.
69.
von der
HeydeS.,
WagnerS.,
CzernyA.mRNA profiling reveals determinants of trastuzumab efficiency in
HER2-positive breast cancer.PLoS One.2015; 10(2):
e0117818.
70.
CollinsD.C.,
CocchigliaS.,
TibbittsP.Growth factor receptor/ steroid receptor cross talk in
trastuzumab-treated breast cancer.Oncogene.2015; 34(4):
525–530.
71.
BaldwinR.M.,
HaghandishN.,
DaneshmandM.Protein arginine methyltransferase 7 promotes breast cancer cell
invasion through the induction of MMP9 expression.Oncotarget.2015; 6(5):
3013–3032.
72.
KöhrmannA.,
KammererU.,
KappM.Expression of matrix metalloproteinases (MMPs) in primary human
breast cancer and breast cancer cell lines: New findings and review of the
literature.BMC Cancer.2009; 9: 188.
73.
VizosoF.J.,
GonzálezL.O.,
CorteM.D.Study of matrix metalloproteinases and their inhibitors in breast
cancer.Br J Cancer.2007; 96(6):
903–911.
